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Abstract: A constellation of pharmacologic treatments for generalized anxiety disorder (GAD) 
have been developed over the past ﬁ  ve decades, although each has a number of potential draw-
backs in clinical practice. This review addresses one potentially new pharmacologic treatment 
for generalized anxiety disorder, the gamma-aminobutyric acid analogue pregabalin. We review 
the mechanism of action, and pharmacokinetic and pharmacodynamic properties of pregabalin 
as well as the results of 5 double-blind, placebo-controlled trials of pregabalin in the treatment 
of generalized anxiety disorder (GAD). Based entirely on data from these industry-sponsored 
(Pﬁ  zer), multi-site clinical trials in patients with GAD, pregabalin appears to be generally well 
tolerated and has rapid onset of action (approximately 1 week), comparable efﬁ  cacy to benzodi-
azepines and lower discontinuation rates compared with other pharmacologic treatments. Thus 
in GAD, a disorder that is often suboptimally responsive to traditional psychotherapeutic and 
psychopharmacologic interventions – secondary to poor efﬁ  cacy, tolerability, and/or side-effects  
– pregabalin may have a primary role in GAD patients, especially in those with certain psychiatric 
comorbidities or individuals who are on multi-drug regimens for medical comorbidities.
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Introduction
With a lifetime prevalence of 4%–7% in the general population, generalized anxiety 
disorder (GAD) is among the most common psychiatric disorders (Kessler et al 2001) 
and is associated with signiﬁ  cant morbidity (World Health Organization Mental Health 
Survey 2004). A constellation of pharmacologic treatments for GAD has been devel-
oped over the past 5 decades, including benzodiazepines, selective-serotonin reuptake 
inhibitors (SSRIs), selective serotonin-norepinephrine reuptake inhibitors (SSNRIs), 
monoamine oxidase inhibitors, and tricyclic antidepressants. However, each of these 
modalities has a number of potential drawbacks in clinical practice. Benzodiazepines 
are associated with cognitive and motor impairment (van Laar et al 1992), pose a 
signiﬁ  cant risk for dependence (Rickels et al 1990), and interact with alcohol. The 
SSRIs and SSNRIs, while efﬁ  cacious in the treatment of GAD, have a delayed onset 
of treatment effect, are associated with sexual side-effects (Kennedy et al 2000), and 
are contraindicated as monotherapy in patients with comorbid bipolar disorder (Keck 
et al 2006) in whom anxiety disorders commonly co-occur (McElroy et al 2001; Simon 
et al 2004). Thus, there is a considerable need to expand our psychopharmacologic 
armamentarium. This review addresses one potentially new pharmacologic treatment 
for generalized anxiety disorder, the γ-aminobutyric acid analogue pregabalin, which 
is currently FDA-indicated for the management of neuropathic pain and post-herpetic 
neuralgia and for adjunctive therapy in patients with partial onset seizures. Neuropsychiatric Disease and Treatment 2007:3(2) 238
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Mechanism of action of pregabalin
Through high afﬁ  nity binding to the α2δ subunit of brain 
voltage-gated calcium channels (N-type), the γ-aminobu-
tyric acid (GABA) analogue pregabalin (Figure 1) decreases 
presynaptic calcium currents (Finker et al 2002) and thus 
decreases calcium-dependent vesicle docking at the presyn-
aptic membrane. Since this process is fundamental for all 
chemical synapses, pregabalin decreases the release of vari-
ous neurotransmitters which have been pathophysiolgically 
implicated in anxiety disorders including glutamate (Dooley 
et al 2000a), substance P (Fehrenbacher et al 2003; Geracioti 
et al 2006), and norepinephrine (Dooley et al 2000b; Strawn 
and Geracioti). However, unlike anxiolytic compounds 
(eg, benzodiazepines) which exert their therapeutic effects 
through binding to GABAA, GABAB, and benzodiazepine 
receptors, pregabalin neither binds directly to these recep-
tors nor augments GABAA currents or affects GABA me-
tabolism (Pﬁ  zer Inc. 2006). Moreover, pregabalin does not 
appear to have functional activity at serotonin, dopamine, or 
norepinephrine receptors and does not alter in vitro reuptake 
kinetics of these monoamines as do traditional antidepres-
sant medications (eg, selective serotonin reuptake inhibitors, 
tricyclic antidepressants)
Pharmacokinetics of pregabalin
Highly lipophilic, pregabalin is rapidly absorbed from the 
gastrointestinal tract and achieves maximum plasma concen-
trations within 1.5 hours of oral administration and has an 
oral bioavailability of ≥90% (Pﬁ  zer Inc. 2006). The Cmax is 
decreased by 25%–30% when pregabalin is taken with food 
but “has no clinically relevant effect on total absorption” 
(Pﬁ  zer Inc. 2006) and can therefore be taken with or without 
food. Because of the lipophilic properties related to substitu-
tion at the 3 position of the GABA molecule, pregabalin is 
thought to rapidly penetrate the central nervous system in 
humans based on cerebrospinal ﬂ  uid and blood–brain barrier 
studies in lower animals (Feng et al 2001; Pﬁ  zer Inc. 2006). 
Moreover, pregabalin dose not exhibit any signiﬁ  cant protein 
binding, has no known drug interactions and, even at high 
doses, does not interact with CYP1A2, CYP2A6, CYP2C9, 
CYP2D6, CYP2E1, or CYP3A4 systems in vivo (Pﬁ  zer Inc. 
2006). Ninety per cent of pregabalin, which has a half-life 
of approximately 6 hours, is excreted renally as unchanged 
drug and it is recommended that dosage should be adjusted 
for patients with creatinine clearance <60 mL/min (see Pﬁ  zer 
Inc. 2006 for further details). 
Pre-clinical studies of pregabalin 
in anxiety states
Lower animal studies have suggested that pregabalin may 
have anxiolytic properties. For example, in rats, pregabalin 
dose-dependently induced anxiolytic-like effects in both 
the conﬂ  ict test and elevated plus maze tests compared with 
placebo (Field et al 2001).
Clinical studies of pregabalin 
in GAD
In a 3-armed study of pregabalin for the treatment of GAD 
(Feltner et al 2003), patients receiving high dose pregabalin 
(600 mg/day) or lorazepam (6 mg/day) but not low-dose 
pregabalin (150 mg/day) signiﬁ  cantly improved compared 
with patients receiving placebo at 4 weeks (mean decrease 
in HAM-A score: 13.2 with high-dose pregabalin compared 
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Figure 1 Chemical structures of γ-amino-butyric acid (GABA), gabapentin, and 
pregabalin.Neuropsychiatric Disease and Treatment 2007:3(2) 239
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with 9.3 with placebo, p = 0.001). However, patients receiving 
high-dose pregabalin and lorazepam were signiﬁ  cantly more 
likely to discontinue than those receiving low-dose pregaba-
lin or placebo, though there was no statistically signiﬁ  cant 
difference between the adverse events in patients treated 
with high-dose pregabalin compared with those receiving 
lorazepam (Feltner et al 2003). 
Pande et al (2003) evaluated two doses of pregabalin 
(50 mg tid and 200 mg tid) in a double-blind, placebo-controlled 
trial which included a lorazepam arm (2 mg tid). This study 
consisted of a 1-week lead-in followed by 4 weeks of double 
blind treatment and a 1-week taper. Baseline-to-endpoint 
decreases in HAM-A score were signiﬁ  cantly greater than 
placebo for both doses of pregabalin and for lorazepam. 
However, this study failed to identify a statistically signiﬁ  cant 
difference between the two dosages of pregabalin with 
respect to outcome HAM-A score, nor were there signiﬁ  cant 
differences in HAM-A scores between patients treated with 
lorazepam and those treated with high-dose pregabalin. 
Pohl and colleagues (2005) compared multiple pregabalin 
dosing regimens (100 mg bid, 200 mg bid, 150 mg tid) in 
a double-blind, placebo-controlled trial in GAD and found 
that all three pregabalin groups had improvement in HAM-A 
scores compared with placebo. As with previous studies in 
this population, pregabalin was generally well tolerated.
Rickels et al (2005), examined 3 doses of pregabalin 
(300 mg/day, 450 mg/day, and 600 mg/day) and alprazolam 
(1.5 mg/day) in the treatment of 454 patients with GAD in 
a randomized, placebo-controlled, multi-site trial. All three 
doses of pregabalin and alprazolam were signiﬁ  cantly supe-
rior to placebo in reduction of HAM-A scores and separation 
from placebo was observed at week one for all treatments. 
A recent double-blind comparison of pregabalin (400 mg/
day and 600 mg/day) and ﬁ  xed-dose venlafaxine (75 mg/day) 
found both dosages of pregabalin and venlafaxine produced 
signiﬁ  cantly greater improvement in HAM-A total score than 
did placebo (Montgomery et al 2006). HAM-A scores at week 
one were signiﬁ  cantly greater than placebo for both dosages of 
pregabalin while venlafaxine-treated patients had statistically 
signiﬁ  cant improvement at week two (Montgomery et al 
2006)
Withdrawal effects of pregabalin 
in patients with anxiety disorders
Of note, clinical trials of pregabalin in the treatment of 
generalized anxiety and social anxiety disorder have in-
cluded withdrawal measures such as the physician withdrawal 
checklist (PWC), a physician-administered instrument which 
measures 20 common withdrawal symptoms and has been 
used extensively to evaluate benzodiazepine withdrawal 
(Rickels et al 1990). Following 4 weeks of pregabalin treat-
ment, Rickels and colleagues (2005) determined PWC scores 
during a 1-week taper and found similar PWC scores in 
all treatment groups (pregabalin 300 mg/day, 450 mg/day, 
and 600 mg/day; alprazolam 1.5 mg/day). However, in the 
subsequent week, during which subjects were medication 
free, signiﬁ  cantly higher withdrawal anxiety was observed 
in patients who had been treated with pregabalin 600 mg/day 
(p < 0.04 vs placebo) (Rickels et al 2005). Interestingly, this 
study did not observe signiﬁ  cant increases in PWC scores 
in those patients who had been treated with alprazolam, 
1.5 mg/day (Rickels et al 2005). Pande et al (2003) found 
PWC scores to be signiﬁ  cantly higher than placebo for pa-
tients receiving lorazepam (6 mg/day) and noted a statistical 
trend (p = 0.06) for patients receiving pregabalin 600 mg/day 
to have increased discontinuation-related anxiety symptoms, 
but found no difference in PWC score between pregabalin 
150 mg/day and placebo (Pande et al 2003). Pohl et al (2005) 
found PWC scores following swift taper or abrupt discon-
tinuation of pregabalin (200 mg/day) to be no different from 
placebo but found PWC scores to be higher than placebo in 
the patients who had been treated with pregabalin (450 mg/
day), though the authors of this study did not consider these 
differences to be clinically signiﬁ  cant (Pohl et al 2005).
Effects of pregabalin on mood 
in GAD patients
Because depressive-spectrum disorders commonly co-occur 
in patients with GAD, and anxiolytics can sometimes worsen 
or improve depressive symptoms, several of the clinical 
trials have included measures of depressive symptoms. Pohl 
and colleagues (2003) observed improvement in Hamilton 
Depression (HAM-D) Scale (17-item) scores for patients 
receiving pregabalin 200 mg tid but did not observe such a 
difference for patients receiving pregabalin 150 mg/day (5.5 
points) or lorazepam 6 mg/day (5.6 points). In a 6-week trial 
comparing pregabalin (400 mg/day and 600 mg/day) with 
ﬁ  xed-dose venlafaxine (75 mg/day) HAM-D scores were 
noted to improve (vs placebo) by 5.3 points (pregabalin 
400 mg/day), 4.9 points (pregabalin 600 mg/day), and 5.1 
points (venlafaxine 75 mg/day) (Montgomery et al 2006). 
Rickels et al (2005) excluded patients with depression in their 
study but did not observe any worsening in HAM-D scores 
in patients receiving pregabalin (300 mg/day, 450 mg/day, Neuropsychiatric Disease and Treatment 2007:3(2) 240
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or 600 mg/day) or alprazolam. Both Feltner et al (2003) and 
Pande et al (2003) excluded patients with current major 
depression, though patients with dysthymia or a history of 
major depression were enrolled. Neither of these studies 
noted worsening of depressive symptoms in any treatment 
arm, though it might be noted that the HAM-D lacks 
sensitivity for the detection of atypical depression. 
Adverse effects and safety of 
pregabalin in patients with anxiety 
disorders
The most frequently reported adverse effects in GAD 
patients included dizziness, somnolence, headache, dry 
mouth, amblyopia, and diarrhea, all of which were more 
frequent in patients receiving pregabalin 600 mg/day com-
pared with those receiving pregabalin 150 mg/day (Pande 
et al 2003; Feltner et al 2003). A study of pregabalin 
400 mg/day and 600 mg/day in GAD also found dizziness 
to be the most common side-effect, followed by somnolence 
(Montgomery et al 2006). A dose-effect with respect to 
these side-effects was observed (Montgomery et al 2006). 
Pohl and colleagues (2005) evaluated bid and tid dosing 
and found no signiﬁ  cant difference in side-effects, though 
the overall adverse effects were similar to those described 
in previous studies: dizziness, somnolence and dry mouth, 
but also euphoria, inco-ordination, ﬂ  atulence, and difﬁ  culty 
concentrating (Pohl et al 2005). 
Given concern for somnolence and other possible central 
nervous system depressant effects, Hindmarch et al (2005) 
evaluated the cognitive and psychomotor effects of pregabalin 
(450 mg/day) compared with alprazolam (3 mg/day) and pla-
cebo in healthy volunteers. In this study pregabalin produced 
“only minor, transient impairment on some objective cognitive 
and psychomotor measures, suggesting a relatively benign CNS 
side-effect proﬁ  le”, while alprazolam treatment resulted in sig-
niﬁ  cant decrement in all measures (Hindmarch et al 2005).
Weight gain has been associated with pregabalin in nearly 
all clinical trials of patients with anxiety disorders (Pande et al 
2003, 2004; Pohl et al 2005; Rickels et al 2005; Montgomery et 
al 2006) and appears to be a dose-related effect. In a 4-week trial, 
mean increases in weight (± SEM) were 1.1 ± 0.2 kg for patients 
receiving 300 mg, 1.4 ± 0. 2 kg for patients receiving 450 mg, 
and 1.9 ± 0.3 kg for patients taking 600 mg, while increases of 
0.9 ± 0.3 kg were observed for patients taking alprazolam (1.5 
mg/day); all increases in weight were statistically signiﬁ  cant 
compared with placebo (Rickels et al 2005). Pande et al (2003) 
similarly observed signiﬁ  cant weight increases of 1.3 kg and 2.2 
kg in patients treated for 4 weeks with pregabalin 150 mg/day 
and 600 mg/day respectively, but did not observe signiﬁ  cant 
weight gain in patients treated with lorazepam (Pande et al 
2003). The studies by Montgomery et al (2006) and Feltner et al 
(2003) noted that some pregabalin-treated patients did experi-
ence >7% increases in body mass but do not include statistical 
comparisons with placebo-treated patients. Finally, Pande 
et al observed mean increases of 0.6 kg and 1.7 kg in patients 
receiving pregabalin 150 mg/day and 600 mg/day for 4 weeks 
respectively, while patients treated with placebo had a mean 
weight loss of 0.1 kg; however, no statistical comparisons were 
reported (Pande et al 2004). The effects of pregabalin on lipid 
proﬁ  les are unknown. 
Discussion 
In a disorder that is often suboptimally responsive to tradi-
tional psychotherapeutic and psychopharmacologic inter-
ventions – secondary to poor efﬁ  cacy, tolerability, and/or 
side-effects – pregabalin may have an emerging role in the 
treatment of GAD. Moreover, pregabalin may have a primary 
role in patients with certain psychiatric comorbidities (eg, 
bipolar disorder, substance dependence) and in patients with 
multiple medical comorbidities who may be taking multiple 
concomitant medications, as pregabalin has no known drug 
interactions (Brodie et al 2005; Pﬁ  zer Inc. 2006). 
The efﬁ  cacy of pregabalin in treating GAD is not surpris-
ing as a number of other antiepileptic drugs have also been 
shown to have anxiolytic properties and to be effective in 
treating patients with anxiety disorders. Valproate has been 
shown to have efﬁ  cacy in the treatment of panic disorder 
(Primeau et al 1990; Woodman and Noyes 1994; Baetz 
and Bowen 1998) and blocks lactate-induced panic attacks 
(Keck et al 1993). The antiepileptic drug carbamazepine 
has efficacy in the treatment of panic disorder (Tondo 
et al 1989), post-traumatic stress disorder (PTSD) (Lipper 
et al 1986), and obsessive compulsive disorder (OCD) (Joffe 
and Swinson 1987). Lamotrigine is potentially effective 
in the treatment of PTSD (Hertzberg et al 1999) and may 
have an adjunctive role in the treatment of refractive 
OCD (Kumar and Khanna 2000). Topiramate has been shown 
to be efﬁ  cacious in open-label trials for PTSD (Berlant and 
van Kammen 2002; Berlant 2004), social phobia disorder 
(Van Ameringen et al 2004) and may have an adjunctive 
role in treatment-resistant OCD (Van Ameringen et al 2006). 
However, unlike previous antiepileptic drugs which primarily 
block sodium and potassium channels or increase cerebral 
GABA concentrations, pregabalin decreases presynaptic Neuropsychiatric Disease and Treatment 2007:3(2) 241
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calcium currents and in doing so decreases the release of 
several neurotransmitters, including glutamate (Dooley 
et al 2000a), substance P (Fehenbacher et al 2003), calcitonin-
gene-related peptide (Fehenbacher et al 2003), and norepi-
nephrine (Dooley et al 2002). Interestingly, many of these 
neurotransmitters have been implicated in the pathogenesis 
GAD or other anxiety disorders (Erikkson et al 1991; 
Geracioti et al 2001; Olsson et al 2004; Geracioti et al 2006). 
As might be expected, agents that pharmacologically dampen 
these systems have therapeutic roles in a number of anxiety 
disorders (Peet and Ali 1986; Furmark et al 2005; Strawn 
and Geracioti 2006). Also, decreases in the activity of these 
or related “fear circuits” that underlie the pathophysiology 
of certain anxiety disorders (Stahl 2004) could explain the 
efﬁ  cacy of pregabalin in patients with GAD. It will be of 
interest to examine the effects of pregabalin in other anxiety 
disorders such as PTSD, panic disorder, or even meal-related 
anxiety in anorexia nervosa (wherein additional beneﬁ  t may 
be conferred by pregabalin-associated weight gain).
Conclusion
Based entirely on data from industry-sponsored (Pﬁ  zer), 
multi-site clinical trials, pregabalin appears to be generally 
well-tolerated in adult patients with generalized anxiety dis-
order and has rapid onset of action (approximately one week) 
as well as comparable efﬁ  cacy to benzodiazepines (Feltner 
et al 2003; Rickels et al 2005). Moreover, discontinuation 
rates observed in the ﬁ  ve published double-blind, placebo-
controlled trials of pregabalin in the treatment of GAD have 
generally been lower than those observed for both benzodiaz-
epines (Geltner et al 2003; Pande et al 2003; Rickels et al 2005) 
and venlafaxine, 75 mg/day (Montgomery et al 2006). 
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